A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2018
At a glance
- Drugs CYC 065 (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Cyclacel Pharmaceuticals
- 09 Nov 2018 Status changed from not yet recruiting to recruiting.
- 04 Oct 2018 Status changed from planning to not yet recruiting, according to a Cyclacel Pharmaceuticals media release.
- 04 Oct 2018 According to a Cyclacel Pharmaceuticals media release, the company has received approval from institutional review board (IRB) for this study.